Hui Liu

7PUBLICATIONS
11CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Apr 26, 2026
Multicenter Real-World Analysis of Glofitamab in Relapsed/Refractory Primary CNS Lymphoma: Clinical Activity, CNS Penetration, and ctDNA Dynamics.

|Jul 03, 2025
Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial.

Wen Lei, Hui Liu, Wenhai Deng

|Apr 18, 2025
Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial.

Wen Lei, Hui Liu, Wenhai Deng

|Apr 02, 2024
CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy.

Shanshan Guo, Wen Lei, Xueli Jin

|Nov 14, 2023
Outcomes and risk factors of SARS-CoV-2 omicron variant in B-cell lymphoma patients following CD19 targeted CAR-T therapy.

Xibin Xiao, Panpan Chen, Yadi Zhong

|Nov 29, 2021
Incidence and prophylaxis of herpes zoster in relapsed or refractory B-cell lymphoma patients after CD19-specific CAR-T cell therapy.

Hui Liu, Ping Li, Aiqi Zhao

Pageof 2

Frequent Collaborators

3 joint publications

Wenhai Deng

3 joint publications

Wenbin Qian

2 joint publications

Wei Chen

2 joint publications

Xiangmin Tong